Novo Nordisk's latest trial results for its next generation obesity drug CagriSema disappointed investors by failing to show superior outcomes to existing drugs. CagriSema, which includes a nascent form of weight loss Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect CagrisSema is a once weekly injection of semaglutide and cagrilintide. Phase 2 clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising Novo Nordisk's Cagrilintide shows promising weight loss in REDEFINE 1 sub analysis, unveiled at EASD 2025 Pharmacally GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction Nature Reviews Gastroenterology & Hepatology